重组活化凝血因子Ⅶ药物的临床应用和研发现状

Clinical application and current research of recombinant activated coagulation factor Ⅶ

凝血因子Ⅶ(FⅦ)是一种维生素K依赖性丝氨酸蛋白酶,作为外源性凝血途径的启动子,主要用于体内产生FⅧ或FⅨ抑制剂的血友病A或B患者的治疗。重组活化凝血因子Ⅶ(rFⅦa)是FⅦ制品最主要的产品,在临床得到广泛的应用。为进一步提高患者疗效和用药顺应性,长效rFⅦa成为当前国际上的研究热点。该文综述了rFⅦa的药理特性、临床应用以及新型在研rFⅦa药物研究进展,为后续研究提供参考。

Coagulation factorⅦ(FⅦ)is a vitamin K-dependent serine protease.As a promoter of exogenous coagulation pathway,it is used mainly to treat patients with hemophilia A or B who produce FⅧ/FⅨinhibitors in vivo.Recombinant activated coagulation factorⅦ(rFⅦa)is the most important of FⅦproducts and has been widely used clinically.In order to continue to improve the efficacy and medication compliance of patients,long-acting rFⅦa has become a hotspot globally.In this paper,the pharmacological characteristics,clinical applications and new long-acting research progress related to rFⅦa are discussed in order to provide reference for subsequent research.